Therapeutic efficacy of intense pulsed light for treatment of meibomian gland dysfunction in glaucoma patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200709006

Enrollment

Registered

2020-07-09

Start date

2020-08-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of meibomian gland dysfunction in glaucoma patients. intense pulsed light&#44

Interventions

IPL lasers will be using the M22 Optima IPL.,Pseudo IPL laser (placebo)

Active Comparator Device,Placebo Comparator No treatment

IPL,Control

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Glaucoma patients treated with 1 or more eye drops that have MGD with more than or equal to 2 items as follows 1. redness or thickening lid margin 2. Telangiectasia 3. reduced secretions of meibum or poor quality secretion of meibum 4. Meibomian gland loss 5. abnormal tear break-up time (TBUT)

Exclusion criteria

Exclusion criteria: 1. there are other diseases of the eyelids and cornea. 2. have a congenital disease affecting the eyes. 3. having a history of corneal transplantation or glaucoma surgery. 4. have been punctual occlusion to treat dry eye before. 5. use eye drops that regularly affect the cornea, including antibiotics and anti-inflammatory drugs. 6. use the following drugs regularly: hormones that treat menopause symptoms (Estrogen, Progestin), Antihistamine, Anti-anxiety disorder and Tricyclic antidepressant, Retinoids 7. light allergies, facial herpes and epilepsy. 8. unable to cooperate with the examination with a slit lamp biomicroscopy and using an IPL 9. people with severe side effects from IPL lasers such as skin colour change that can be noticeable, allergic rash or scarring.

Design outcomes

Primary

Measure	Time frame
Ocular surface symptom Visit 0, day15, day30, day45, day60, day75 Ocular surface symptom questionnaire,Ocular surface symptom Visit 0, day15, day30, day45, day60, day75 Ocular surface symptom questionnaire	—

Secondary

Measure	Time frame
Tear osmolality Visit 0, day75 Tear osmolality test card	—

Contacts

Public ContactPinnita Prabhasawat

Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University

pinnita.t@gmail.com+6624198037

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026